Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldafermin in PSC (ALPINE-PSC)
NCT06654726Phase 3Withdrawn
- Sponsor
- NGM Biopharmaceuticals
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of aldafermin in Primary Sclerosing Cholangitis (PSC), sponsored by NGM Biopharmaceuticals. Planned start Oct 2024; status: withdrawn.
02
Drugs
aldafermin
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT06654726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654726.